| For: | Mangia A, Mottola L, Santoro R. Interleukin 28B polymorphisms as predictor of response in hepatitis C virus genotype 2 and 3 infected patients. World J Gastroenterol 2013; 19(47): 8924-8928 [PMID: 24379617 DOI: 10.3748/wjg.v19.i47.8924] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v19/i47/8924.htm |
| Number | Citing Articles |
| 1 |
Simone Susser, Eva Herrmann, Christian Lange, Nabila Hamdi, Tobias Müller, Thomas Berg, Dany Perner, Stefan Zeuzem, Christoph Sarrazin, Ferruccio Bonino. Predictive Value of Interferon-Lambda Gene Polymorphisms for Treatment Response in Chronic Hepatitis C. PLoS ONE 2014; 9(11) doi: 10.1371/journal.pone.0112592
|
| 2 |
|
| 3 |
Chia‐Yen Dai, Wan‐Long Chuang, Ming‐Lung Yu. Variants of the inosine triphosphate pyrophosphatase gene and relapse risk following treatment for HCV genotype 2/3. Hepatology 2014; 60(6) doi: 10.1002/hep.27109
|
| 4 |
Jessica Cusato, Sarah Allegra, Lucio Boglione, Amedeo De Nicolò, Lorena Baietto, Giuseppe Cariti, Giovanni Di Perri, Antonio D'Avolio. Vitamin D Pathway Gene Variants and HCV-2/3 Therapy Outcomes. Antiviral Therapy 2015; 20(3) doi: 10.3851/IMP2853
|
| 5 |
Alessandro Antonelli, Silvia Martina Ferrari, Ilaria Ruffilli, Poupak Fallahi. Cytokines and HCV-related autoimmune disorders. Immunologic Research 2014; 60(2-3) doi: 10.1007/s12026-014-8569-1
|
| 6 |
P Ranjan, GJ Fletcher, M Radhakrishnan, J Sivakumar, PS Premkumar, A Goel, UG Zachariah, P Abraham. Association of interleukin-28B rs12979860 and rs8099917 polymorphisms with sustained viral response in hepatitis C virus genotype 1 and 3 infected patients from the Indian subcontinent. Indian Journal of Medical Microbiology 2016; 34(3) doi: 10.4103/0255-0857.188329
|
| 7 |
L. Nosotti, A. Petrelli, D. Genovese, S. Catone, C. Argentini, S. Vella, A. Rossi, G. Costanzo, A. Fortino, L. Chessa, L. Miglioresi, C. Mirisola. Distribution of IL28B Polymorphism in a Cohort of Italians and Immigrants with HCV Infection: Association with Viraemia, Stage of Fibrosis and Response to Treatment. Journal of Immigrant and Minority Health 2017; 19(4) doi: 10.1007/s10903-016-0444-9
|
| 8 |
Thomas Kuntzen, Sereina Kuhn, Daniela Kuntzen, Burkhardt Seifert, Beat Müllhaupt, Andreas Geier, Golo Ahlenstiel. Influence of Ribavirin Serum Levels on Outcome of Antiviral Treatment and Anemia in Hepatitis C Virus Infection. PLOS ONE 2016; 11(7) doi: 10.1371/journal.pone.0158512
|
| 9 |
Bianca Heinrich, John P. Bilello. Antimicrobial Drug Resistance. 2017; doi: 10.1007/978-3-319-46718-4_39
|
| 10 |
E. Riva, C. Scagnolari, O. Turriziani, G. Antonelli. Hepatitis C virus and interferon type III (interferon-λ3/interleukin-28B and interferon-λ4): genetic basis of susceptibility to infection and response to antiviral treatment. Clinical Microbiology and Infection 2014; 20(12) doi: 10.1111/1469-0691.12797
|
| 11 |
Valli De Re, Mariangela De Zorzi, Laura Caggiari, Gianfranco Lauletta, Maria Lina Tornesello, Elisa Fognani, Marta Miorin, Vito Racanelli, Luca Quartuccio, Laura Gragnani, Sabino Russi, Fabio Pavone, Michela Ghersetti, Elena Garlatti Costa, Pietro Casarin, Riccardo Bomben, Cesare Mazzaro, Giancarlo Basaglia, Massimiliano Berretta, Emanuela Vaccher, Francesco Izzo, Franco Maria Buonaguro, Salvatore De Vita, Anna Linda Zignego, Paolo De Paoli, Riccardo Dolcetti. HCV-related liver and lymphoproliferative diseases: association with polymorphisms of IL28B and TLR2. Oncotarget 2016; 7(25) doi: 10.18632/oncotarget.9303
|
| 12 |
Ching-Chih Hu, Chih-Lang Lin, Liang-Che Chang, Cheng-Hung Chien, Li-Wei Chen, Ching-Jung Liu, Rong-Nan Chien. Interleukin-28B gene non-TT allele strongly predicts treatment failure for genotype 1 infected chronic hepatitis C patients with advanced fibrosis: a case control study. BMC Infectious Diseases 2015; 15(1) doi: 10.1186/s12879-015-0888-x
|
| 13 |
Jacqueline C.M. Paterson, Michael H. Miller, John F. Dillon. Update on the treatment of hepatitis C genotypes 2–6. Current Opinion in Infectious Diseases 2014; 27(6) doi: 10.1097/QCO.0000000000000114
|
| 14 |
Qingxian Cai, Xiaohong Zhang, Chaoshuang Lin, Xiaoqiong Shao, Yujuan Guan, Hong Deng, Min Wei, Mingshou Huang, Zefang Ren, Ling Lu, Yongyu Mei, Min Xu, Jianyun Zhu, Haiyan Shi, Guoli Lin, Ying Liu, Fengyu Hu, Qiumin Luo, Yun Lan, Fengxia Guo, Zhixin Zhao, Zhiliang Gao, Dimitrios Paraskevis. 24 versus 48 Weeks of Peginterferon Plus Ribavirin in Hepatitis C Virus Genotype 6 Chronically Infected Patients with a Rapid Virological Response: A Non-Inferiority Randomized Controlled Trial. PLOS ONE 2015; 10(10) doi: 10.1371/journal.pone.0140853
|
| 15 |
Meng Wang, Jian-sheng Li, Yu Ping, Zhi-qin Li, Li-ping Wang, Qian Guo, Zhen Zhang, Dong-li Yue, Fei Wang, Teng-fei Zhang, Mohammad Serajul Islam, Yi Zhang. The host HLA-A*02 allele is associated with the response to pegylated interferon and ribavirin in patients with chronic hepatitis C virus infection. Archives of Virology 2015; 160(4) doi: 10.1007/s00705-015-2361-y
|
| 16 |
Michael S. Forman, Alexandra Valsamakis.
Manual of
Clinical Microbiology. 2015; doi: 10.1128/9781555817381.ch92
|